Simulations Plus, Inc. (SLP) Q4 2025 Earnings Call Transcript

Simulations Plus reported Q4 revenue of $17.5M (down 6% YoY) and full-year 2025 revenue of $79.2M (up 13% YoY), with software representing 58% of FY revenue; adjusted EBITDA rose to $22.0M (28% of revenue) and adjusted diluted EPS was $1.03 vs. $0.95 a year ago. The company recorded a $77.2M noncash impairment that produced a FY net loss of $64.7M (loss per share $3.22), but finished the year with $32.4M cash, no debt and backlog up 28% to $18M. Management reiterated FY2026 guidance of $79–82M revenue, adjusted EBITDA margin 26–30% and adjusted EPS $1.03–1.10, while flagging near-term market uncertainty; strategic priorities include integrating Pro-ficiency, rolling out AI/cloud capabilities (GastroPlus 10.2) and pursuing further M&A to drive long-term biosimulation adoption.

Analysis

Market structure: Simulations Plus (SLP) is pivoting from point tools to an integrated biosimulation+AI+cloud ecosystem—this benefits SLP (software + high-margin recurring revenue) and cloud providers (AMZN, MSFT) who supply compute. Services demand remains lumpy (backlog $18M, +28% YoY) so short-term beneficiaries are flexible consultancies that can scale; losers are small point-solution vendors and low‑margin CROs whose pricing power is weaker. Expect pricing power to slowly recover as SLP annual price increases and module monetization are rolled into renewals.

Risk assessment: Key tail risks include (1) another large program cancellation (one large cancellation materially hit Q4), (2) rapid commoditization/entry by Big Tech AI tools that undercut specialized regulators‑grade models, and (3) delayed client IT/cloud adoption that pushes recurring revenue conversion out >12 months. Immediate horizon (days–weeks): Q1 seasonality and 3–5% headwind; short term (1–3 months): Investor Day (Jan 21) is primary catalyst; long term (4–24 months): successful AI/cloud integration determines re‑rating. Hidden dependency: revenue is lumpy by project timing and renewal cadence—backlog conversion assumptions are key.

Trade implications: Tactical long bias into Investor Day—SLP is a classic event/catalyst trade with defined downside (cash runway $32M, no debt) and asymmetric upside if renewals/backlog trends improve. Use protective options to limit downside; consider a dollar‑neutral pair trade long SLP vs short IQV (IQV) to express biosimulation software outperformance vs legacy CRO services. Rotate 2–5% portfolio weight into cloud infra names (AMZN, MSFT) to capture compute tailwinds.

Contrarian angle: The market underestimates the monetization of AI‑assisted modules—if renewal fee recovery reaches ≥90% and biotech funding rebounds (a 10–20% uplift in funded rounds over 6 months), upside could be +20–40% over 12 months. Conversely, consensus may be underpricing the risk of another large cancellation or failed product adoption; set hard stop/triggers (renewal rate <80% or backlog down >15% q/q) to avoid drawdowns. Historical parallel: niche scientific software vendors re‑rated after becoming platform incumbents; timing was 6–24 months, not immediate.

Key Decisions for Investors

• Establish a 2–3% long position in SLP ahead of Investor Day (Jan 21, 2026); size incremental add (another 1–2%) only if Q1 bookings/backlog growth >10% q/q or renewal rate rebounds to ≥90% within 60 days.
• Hedge new SLP equity exposure by purchasing 3‑month protective puts (~Mar 2026 expiry) sized to cap downside at 8–12% of position value, OR buy a Feb–Mar 2026 call spread 10%–30% OTM to capture post‑Investor Day re‑rating with limited debit risk.
• Implement a dollar‑neutral pair trade: long SLP vs short IQV (IQV) with equal dollar exposure; unwind if SLP underperforms IQV by >10% over 60 days or if SLP renewal rate falls below 80%.
• Rotate 2–4% of portfolio into cloud compute exposure (AMZN, MSFT) to capture increased demand for compute/AI in biosimulation; trim exposure if enterprise cloud capex growth decelerates below +5% YoY in next two quarters.